Latest stories on RGEN
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures
TipRanks73 · bullishearnings
Canaccord reiterates Hold on Repligen stock, keeps $145 target
Investing.com Analyst Ratings50 · neutralanalyst
Repligen soars 16% after blockbuster earnings, FY25 guidance upgrade
Seeking Alpha73 · bullishearnings
Repligen projects $813M-$834M 2026 revenue amid BioLife deal and raised $2.03-$2.09 EPS
Seeking Alpha73 · bullishearnings
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Repligen Q2 Earnings Call Highlights
Yahoo Finance63 · neutralearnings
Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance
InvestorsHub68 · bullishearnings
Why is Repligen stock rallying today?
Investing.com Markets50 · neutralgeneral
REPLIGEN CORP (RGEN) files 8-K
SEC 8-K50 · neutralgeneral
Repligen Non-GAAP EPS of $0.54 beats by $0.09, revenue of $204.1M beats by $2.7M
Seeking Alpha68 · bullishearnings
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Business Insider63 · neutralearnings
Repligen Q2 2026 Earnings Preview
Seeking Alpha55 · neutralearnings
Key deals this week: Stripe, IBM, Repligen, LXP Industrial Trust and more
Seeking Alpha50 · neutralm&a
Canaccord reiterates Hold on Repligen stock after BioLife deal
Investing.com Analyst Ratings50 · neutralm&a
Repligen Corporation (RGEN) M&A Call Transcript
Seeking Alpha50 · neutralm&a
Repligen Corporation (RGEN) BioLife Solutions, Inc., - M&A Call - Slideshow
Seeking Alpha50 · neutralm&a
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Yahoo Top68 · bullishm&a
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife
Investing.com Markets63 · neutralm&a
Repligen to Acquire BioLife, Expanding Cell Therapy Reach
TipRanks63 · neutralm&a
REPLIGEN CORP (RGEN) files 8-K
SEC 8-K50 · neutralgeneral
Repligen’s $1.5B BioLife Acquisition Poised to Reshape Cell Therapy Market with Accretive Growth
July 22, 2026
MarketChameleon73 · bullishm&a
Repligen's $1.5 Billion BioLife Acquisition Boosts Cell Therapy Market Presence and Earnings Outlook
MarketChameleon73 · bullishm&a
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
Yahoo Finance68 · bullishm&a
Repligen to buy BioLife Solutions in $1.5 billion deal
Reuters63 · neutralm&a
Repligen to buy BioLife Solutions in $1.5B stock-and-cash deal
Seeking Alpha68 · bullishm&a